Bringing the Oncology Community Together

Dr. Cooperberg on Prostate Cancer Stage Migration

Matthew Cooperberg, MD, MPH
Published Online: Tuesday, March 12, 2013
Matthew Cooperberg, MD, MPH, Assistant Professor of Urology; Epidemiology & Biostatistics, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses the imminent stage migration that is likely to occur as new therapies become available expressly for metastatic prostate cancer.

The boundary between M0 (no metastasis) and M1 (metastatic) prostate cancer is arbitrary and depends heavily on the methods used to detect metastasis. In fact, Cooperberg stresses, most patients with M0 prostate cancer likely have microscopic metastasis that cannot be detected by standard bone scans.

These stages have remained unchanged to date because therapeutic options were limited. However, recent advances have brought an abundance of effective treatments into this space, providing incentive to pursue more advanced diagnostic approaches, such as fluorine-based PET scans.

This stage migration will not be without consequences, Cooperberg notes. While the agent sipuleucel-T (Provenge) has a fixed cost, other treatments can be given for an open-ended timeframe. Beginning these therapies earlier, and ultimately providing them for a longer period of time, may dramatically impact costs.

Related Articles
Early Detection of Metastatic Prostate Cancer
In this segment, panelists discuss advanced imaging techniques that can be used to detect metastases earlier for patients with castration-resistant prostate cancer.
Adding ADT to RT Reduces Risk of Progression in Localized Prostate Cancer
Patients with localized prostate cancer at intermediate or high risk for progression experience better outcomes when 6 months of androgen deprivation therapy is added to standard radiotherapy.
Pretreatment Genetic Test Predicts Recurrence in Prostate Cancer
A novel 100-locus DNA signature obtained from pretreatment biopsies accurately classified 75% of patients with untreated prostate cancer as low- or high-risk.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
OncLive Resources

OncLive TV
Oncology Nurses
Web Exclusives

About Us
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.